Marinus Pharmaceuticals Inc (MRNS) concluded trading on Thursday at a closing price of $0.30, with 47.64 million shares of worth about $14.29 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -79.15% during that period and on October 24, 2024 the price saw a loss of about -82.49%. Currently the company’s common shares owned by public are about 54.58M shares, out of which, 47.93M shares are available for trading.
Stock saw a price change of -82.99% in past 5 days and over the past one month there was a price change of -82.99%. Year-to-date (YTD), MRNS shares are showing a performance of -97.28% which decreased to -95.60% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.05 but also hit the highest price of $11.26 during that period. The average intraday trading volume for Marinus Pharmaceuticals Inc shares is 522.64K. The stock is currently trading -82.41% below its 20-day simple moving average (SMA20), while that difference is down -80.90% for SMA50 and it goes to -92.65% lower than SMA200.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Marinus Pharmaceuticals Inc (NASDAQ: MRNS) currently have 54.58M outstanding shares and institutions hold larger chunk of about 67.86% of that.
The stock has a current market capitalization of $16.30M and its 3Y-monthly beta is at 1.15. It has posted earnings per share of -$2.66 in the same period. It has Quick Ratio of 2.15. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for MRNS, volatility over the week remained 24.14% while standing at 10.44% over the month.
Stock’s fiscal year EPS is expected to rise by 26.20% while it is estimated to increase by 63.83% in next year. EPS is likely to grow at an annualized rate of 20.00% for next 5-years, compared to annual growth of 6.04% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Oppenheimer on September 23, 2024 offering an Outperform rating for the stock and assigned a target price of $6 to it. On April 16, 2024, Robert W. Baird Downgrade their recommendations, while on April 15, 2024, RBC Capital Mkts Downgrade their ratings for the stock with a price target of $3. Stock get a Perform rating from Oppenheimer on August 11, 2023.
